Hanmi Pharmaceutical has launched Countmate, a fully automated vial dispensing machine designed to meet the specific needs of ...

The treatment was approved in 2024 for chronic graft-vs-host disease after failure of at least 2 prior lines of systemic therapy in patients weighing at least 40kg. The Food and Drug ...

(RTTNews) - Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that the U.S. Food and Drug Administration has approved Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The Companies ...

Hanmi Pharmaceutical's Countmate targets the vial-based medication packaging market in Canada and the US. Hanmi ...

Incyte, a global biopharmaceutical company on a mission to Solve On, and Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company, announced that the US Food and Drug Administration (FDA) ...

The FDA has approved Incyte’s and Syndax’s Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes for the treatment of chronic graft-versus-host disease (GVHD) in adults and pediatric patients ...

SEOUL, South Korea, Feb. 13, 2025 /CNW/ -- Hanmi Pharmaceutical's Global Business Headquarters Overseas Sales Team is making ...

The FDA has approved 2 additional vial sizes of Niktimvo™ (axatilimab-csfr), 9mg/0.18mL and 22mg/0.44mL, in addition to the 50mg/mL size.